Indian went to China for CAR T Cell therapy – Patient story

Mr. Rakesh (name changed), a 66-year-old individual from India, began his medical journey in April 2018. A biopsy of a mass in the left arm, along with a whole-body PET-CT scan, confirmed the diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL). This initiated a stringent treatment protocol designed to address the disease.

Mr. Rakesh underwent a total of six cycles of the R-EPOCH chemotherapy regimen, followed by three cycles of the R-GDP regimen, and subsequently received two additional cycles of the same regimen. This intensive chemotherapy regimen occurred from April 2018 to October 2019, marked by perseverance and resilience amid challenges.

During the October 2019 PET-CT re-evaluation, new metabolic irregularities were identified in the right calcaneus and the right distal femur, despite the challenging treatment regimen. Mr. Rakesh pursued the expertise of a hospital in Beijing, recognizing it as the leading CAR-T center worldwide.

In November 2019, Mr. Rakesh initiated a new phase of treatment with our medical team. Comprehensive examinations indicated dim-positive CD19 and markedly strong positive CD22, suggesting significant residual tumor activity. Based on these findings, the decision was made to implement CD19+CD22 CAR-T cell therapy, an advanced method aimed at addressing the ongoing malignancy.

Post-infusion, Mr. Rakesh exhibited a manageable grade 2 Cytokine Release Syndrome (CRS) and subsequently recovered rapidly. In January 2020, he was discharged following favorable results from a recent PET-CT scan, which indicated tumor regression and a significant reduction in metabolic activity.

Mr. Rakesh’s journey highlights the significant impact of advanced medical interventions in oncology. In initiating a long-term outpatient follow-up regimen, the emphasis is on maintaining the achieved vitality and preventing disease recurrence.

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Best Cancer Hospitals in China 2025
• Susan Hau

  https://cancerfax.com/author/susan/

  Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
• Susan Hau

  https://cancerfax.com/author/susan/

  Treosulfan with fludarabine is approved by the USFDA as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS
• Susan Hau

  https://cancerfax.com/author/susan/

  Fam-trastuzumab deruxtecan-nxki is approved by the USFDA for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer